fifteen post-menopausal patients with advanced breast cancer were treated with the lh-rh agonist leuprorelin ( d-leu6-des-gly10-gn-rh-ethylamide ) given in a dosage of 7.5 mg as a monthly subcutaneous depot injection , to assess the clinical activity and endocrine response to treatment .
C0085272
leuprorelin
C0023610
gn-rh